Drug Pricing
has transformed health care for low-income families and individuals, especially children, pregnant mothers, parents and children with disabilities and special health care needs.
Featured
More On Drug Costs …
Explore this content in more detail
Go to the search page to sort and filter these results by date, topic, subtopic, author, and type.
-
Several Key Questions about Trump Administration’s Drug Pricing Deals and Their Impact on Medicaid Remain Unaddressed
[Editor’s Note: This blog was updated on November 21, 2025, to reflect changes to the Request for Applications.] On November 6, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a new Center for Medicare and Medicaid Innovation (CMMI) model to implement pricing agreements with two drug manufacturers — Pfizer and AstraZeneca — which…
-
Many Unanswered Questions: Will the Trump Administration’s Drug Pricing Deals Result in Any Cost Savings for State Medicaid Programs?
Over the last month, the White House has widely touted pricing agreements from two drug manufacturers — Pfizer and AstraZeneca — which it claims will result in substantial prescription drug cost savings for state Medicaid programs. According to the White House, under these agreements, the manufacturers will provide “Most Favored Nation (MFN)” prices, based on…
-
New Federal Budget Law Spells Trouble for Patients with Insulin-Requiring Diabetes
By: Billy Dering, Amy Killelea, and Christine Monahan (Georgetown University Center on Health Insurance Reforms) The recently enacted federal budget law is set to significantly roll back critical provisions of the Affordable Care Act (ACA) that have expanded health insurance coverage to millions. The law takes aim at health care programs that primarily serve low- and moderate-…
-
Medicaid Drug Rebate Program News and Notes, 2024 Edition
Periodically I write up news on the Medicaid Drug Rebate Program (MDRP) and here’s another (albeit overdue) edition highlighting some recent MDRP policy developments: The Centers for Medicare and Medicaid Services (CMS) will not finalize its proposal to require manufacturers to “stack” discounts when determining best price under the MDRP. The best price requirement, which…
-
Draft Senate Finance Committee Bill Addressing Drug Shortages Includes Broad Rollback of Medicaid Inflation-Related Rebates for Generic Drugs, Raises Serious Concerns
Congress has been examining ways to address the ongoing problem of generic drug shortages, especially with cancer patients continuing to face severe shortages of widely used generic chemotherapy drugs. Both the House Energy and Commerce Committee and the Senate Finance Committee have held hearings on generic drug shortages, with the Senate Finance Committee also issuing…